MEDX Stock Overview
Designs, produces, and sells high-precision devices and services for the healthcare, consumer, and industrial end markets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
medmix AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 8.34 |
| 52 Week High | CHF 19.24 |
| 52 Week Low | CHF 8.20 |
| Beta | 0.77 |
| 1 Month Change | -6.19% |
| 3 Month Change | -12.03% |
| 1 Year Change | -55.50% |
| 3 Year Change | -82.26% |
| 5 Year Change | n/a |
| Change since IPO | -81.05% |
Recent News & Updates
Recent updates
medmix AG (VTX:MEDX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Aug 11
medmix (VTX:MEDX) Is Reinvesting At Lower Rates Of Return
Dec 19An Intrinsic Calculation For medmix AG (VTX:MEDX) Suggests It's 21% Undervalued
Oct 27Investors Could Be Concerned With medmix's (VTX:MEDX) Returns On Capital
Aug 16There May Be Reason For Hope In medmix's (VTX:MEDX) Disappointing Earnings
Feb 28medmix (VTX:MEDX) May Have Issues Allocating Its Capital
Jan 14Shareholder Returns
| MEDX | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | -5.8% | -1.5% | -2.3% |
| 1Y | -55.5% | 2.4% | 1.2% |
Return vs Industry: MEDX underperformed the Swiss Medical Equipment industry which returned 2.4% over the past year.
Return vs Market: MEDX underperformed the Swiss Market which returned 1.2% over the past year.
Price Volatility
| MEDX volatility | |
|---|---|
| MEDX Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 4.0% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: MEDX has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: MEDX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1922 | 2,695 | n/a | www.medmix.swiss |
medmix AG designs, produces, and sells high-precision devices and services for the healthcare, consumer, and industrial end markets worldwide. The company operates through Dental, Drug Delivery, Surgery, Industry, and Beauty segments. The company offers dental products, including mixing tips, dispensers, needles, accessories, and service solutions for various applications, such as prosthetics, adhesives, restoratives, prevention, esthetics and endodontics; drug delivery devices that are used to inject fertility drugs and growth hormones; and to treat niche diabetes indications, osteoporosis, and rare diseases; and mixing and delivery devices which are used to inject bone tissue, and to apply hemostatic sealants for internal and external wound treatment during surgical procedures.
medmix AG Fundamentals Summary
| MEDX fundamental statistics | |
|---|---|
| Market cap | CHF 337.73m |
| Earnings (TTM) | -CHF 1.80m |
| Revenue (TTM) | CHF 479.70m |
0.7x
P/S Ratio-189.0x
P/E RatioIs MEDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDX income statement (TTM) | |
|---|---|
| Revenue | CHF 479.70m |
| Cost of Revenue | CHF 323.40m |
| Gross Profit | CHF 156.30m |
| Other Expenses | CHF 158.10m |
| Earnings | -CHF 1.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 32.58% |
| Net Profit Margin | -0.38% |
| Debt/Equity Ratio | 62.4% |
How did MEDX perform over the long term?
See historical performance and comparisonDividends
6.0%
Current Dividend Yield-1,174%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 18:40 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
medmix AG is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christoph Gretler | Credit Suisse |
| Eugen Perger | Research Partners AG |